All In Biotech

Drug Trial Radar · NCT00865579

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Last checked: Nov 19, 2026Latest source record: Sep 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

964

Actual

Start

Apr 2009

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Newron Pharmaceuticals SPAIndustry
Sponsor type
Industry
First posted
Mar 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Parkinson's Disease (PD) is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the major DA metabolising enzyme in humans. Safinamide is an inhibitor of MAO-B. This study is to evaluate the long term safety and tolerability of safinamide in PD patients, that have already completed a previous clinical study with Safinamide. The physical and neurological conditions as well as other safety parameters will get compared from baseline to subsequent visits.

Conditions

  • Parkinson's Disease

Interventions

  • SafinamideDrug

    The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm). Trial Medication is to be taken once daily, in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Physical ExamsTime frame: Anticipated time frame up to 3 years
  2. Change from baseline in Neurologic ExamsTime frame: Anticipated time frame up to 3 years
  3. Change from baseline in Vital SignsTime frame: Anticipated time frame up to 3 years
  4. Change from baseline in Laboratory EvaluationsTime frame: Anticipated time frame up to 3 years
  5. Change from baseline in ElectrocardiogramsTime frame: Anticipated time frame up to 3 years
  6. Summary of Participants who had Adverse ExperiencesTime frame: Anticipated time frame up to 3 years
  7. Change from baseline in Unified Parkinson's Disease Rating Scale (UPDRS)Time frame: Anticipated time frame up to 3 years
  8. Change from baseline in Dermatologic ExamsTime frame: Anticipated time frame up to 3 years
  9. Change from baseline in Ophthalmologic ExamsTime frame: Anticipated time frame up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Timuș, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.